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Introduction
The diversity of the clinical symptoms of cystic fibro-
sis and the manifestation in different periods of life
with variable intensity, often lead to a delay in CF clin-
ical diagnosis. The main goals of newborn screening
programmes are the early diagnosis of inborn diseases,
before the symptoms appear, to enable early introduc-
tion of therapy [1].
In Poland CF NBS started in January 1999. Until
2003 it was a pilot regional programme based on
IRT/F508del/IRT protocol [2]. In September 2006 
a move to National CF NBS was initiated, extending
gradually to cover the whole of Poland by July 2009
[3].
Screening for CF is based on a four tiers protocol
IRT/DNA/IRT/sweat test (covering the 16 most com-
mon mutations in the Polish population, and thanks to
gene sequencing allowing the diagnosis of over 500
mutations). Intermediate tier consists of IRT resam-
pling in infants with the highest IRT values (99th per-
centile cut-off). The final diagnosis is based on CFTR
gene mutation analysis and sweat test (conventional
pilocarpine-iontophoresis and conductometric Nanod-
uct) combined with clinical examination. 
Infants with positive neonatal CF screening results
(increased second IRT at 4 weeks and/or one or two
mutations) are called to the CF Centre at our Institute
for verification. The same day 2 sweat tests are per-
formed – a classical pilocarpine iontophoresis and 
a conductometric Nanoduct. Values of Cl- in sweat >40
mmol/L and NaCl >60 mmol/L are considered diag-
nostic for CF.
There are ongoing discussions about the rationale
for CF NBS. We would like to add another positive
argument towards the balance in favour of NBS. We
present families where elder siblings were diagnosed
thanks to CF NBS programmes covering newborns
who were CF or CFTR gene carriers.
Case reports
In Table 1 the data of the 5 families described are
presented. Four of them (numbers: 1-4) were diag-
nosed in the pilot CF NBS. An infant from family
number 5 and the youngest child from family num-
ber 4 were diagnosed in the current CF NBS pro-
gramme [3]. 
The diagnosis of pancreatic function was based on
clinical symptoms and faecal elastase assessment.
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Case series
Family 1
A baby girl was called to our CF centre due to remain-
ing increased IRT still in the second sample and one
mutation F508del identified. The girl at the time of
consultation had no clinical symptoms and borderline
sweat tests. Further DNA analysis and a second sweat
test were performed at the age of 6 months.
The mother brought also her 5 year old son, who
was being followed by a gastroenterologist due to rec-
tal prolaps and steatorrhea. Periodically he was treated
with pancreatic enzymes. From the second year of life
he had recurrent respiratory infections. He was short
and underweight with visible finger clubbing. He had
chest hyperresonance in physical examination and
fibrotic changes CXR. His sweat tests were high. His
genotype was F508del/1717-1. For the girl the 1717-1
mutation was not present. This fact was decisive for
her diagnosis as an F508del carrier. 
Family 2, 3, 5
Infants from these families, recalled to our centre due
to positive screening tests, had CF diagnosis con-
firmed with sweat tests and CFTR mutations. Their
siblings were invited for sweat tests. Those with ele-
vated values were subsequently DNA tested. All 3 of
them had typical respiratory symptoms. Two of them
(from families number 2 and 5) also had symptoms of
pancreatic insufficiency (malnutrition, diarrhea) con-
firmed with faecal elastase.
Family 4
A baby girl from multiple children family was picked
up in a pilot screening programme due to increased
IRT and one F508del mutation. She was in good clin-
ical status. Both sweat tests were within normal lim-
its. In her 5th month of age the sweat tests were
repeated, again the values were normal. The parents
did not agree to keep DNA for further procedures and
did not come for future consultations. Four years
later the girl's 10 years old sister was referred to us
for consultation because of nasal polyps and chronic
sinusitis. She had normal somatic development and
was pancreatic sufficient. Sweat tests were within
norms, as were spirometric values. Further DNA
analysis was performed and two CFTR mutations:
F508del/3849+ 10kb>T were identified in both sis-
ters. After that diagnosis, the mother brought to our
centre the eldest brother (13 years old). He had a
chronic cough and frequent respiratory tract infec-
tions. His somatic development was normal, but there
were abnormalities observed in his respiratory sys-
tem. Inflammatory changes were heard in his lungs in
auscultation, the thickening of bronchial walls was
seen in his CXR and sinal polyps were identified by
CT, his lung function was below norms: FEV1 80%,
FVC 75%. Sweat tests values were equivocal. DNA
analysis revealed the same genotype as by his sisters.
The seventh child of the family did not undergo pre-
natal diagnosis due to the advanced pregnancy at the
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Table 1. Characteristics of infants identified by CF NBS and their CF siblings (sweat tests values, genotypes). Preliminary DNA analy-
sis – from the blood spot at the filter paper taken on the 3rd day of life.
time of the other siblings' diagnosis. She was covered
by an extended DNA analysis within the current CF
NBS. The identical genotype as by her elder siblings
was discovered. Her sweat tests were borderline. The
child's somatic development and pancreatic function
were normal. The remaining 3 children were consult-
ed in our centre. Their sweat tests values were within
normal limits and no abnormalities were found dur-
ing physical examination. Because in CF patients
with 3849+10kbC>T mutations the sweat test read-
ings may not be elevated, DNA analysis was per-
formed and revealed that two of them were
3849+10kbC>T carriers. One child was free from
CFTR mutations.
Discussion
In all the described families elder siblings of infants
with positive screening test results owe their diagnosis
to the screening programme, which did not cover them
directly. All of them were worrying their families pre-
senting the symptoms typical of CF which had been
reported to health professionals. 
The symptoms are typical but not specific for CF,
and can be misdiagnosed as allergies, food intolerance
and common respiratory tract infections, despite regu-
lar CF educational campaigns and postgraduate CF
training.
Cases with borderline sweat tests and pancreatic suf-
ficiency are the most problematic. Polish guidelines rec-
ommend a value of 40 mmol/l (pilocarpine iontophore-
sis) [3], international guidelines suggest to lower the
infant sweat test value limit to 30 mmol/l [4-6].
However, in family number 4, children with CF had
sweat test values even below 30mmol/. In their situa-
tion a larger panel of mutations incorporated in the
standard CF NBS procedure (including 3849+10kb)
was diagnostic.
Based on our experience with described families
we conclude as follows:
• In the case of a carrier or CF diagnosed within
CF NBS programme, family history concerning
siblings should be reviewed.
• Sweat testing of the siblings of diagnosed CF per-
sons is recommended by international and Polish
standards of CF care [3,4,6,7]. In the case of car-
rier or CF diagnosis in CF NBS, genetic coun-
selling of the parents is very important [1,3].
• Appropriate screening strategy for the given
population enables diagnosis even in the case
of equivocal sweat tests. The panel of chosen
mutations should include CF causing mutations
common in the given population associated with
normal or equivocal sweat electrolyte values (in
particular, 3849+10kb>T) [1].
• The cases presented in this article can be a
memorable illustration why the opportunity to
diagnose older siblings after CF screening of an
infant must not be missed. 
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